NBTX

NBTX

USD

Nanobiotix S.A. American Depositary Shares

$19.330+0.560 (2.983%)

Prix en Temps Réel

Healthcare
Biotechnologie
France

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$18.770

Haut

$20.261

Bas

$18.580

Volume

0.07M

Fondamentaux de l'Entreprise

Capitalisation Boursière

1.1B

Industrie

Biotechnologie

Pays

France

Statistiques de Trading

Volume Moyen

0.08M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $2.76Actuel $19.330Haut $30.35

Actualités Connexes

GlobeNewswire

NANOBIOTIX to Participate in Investor Conferences the Week of November 10th

PARIS and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ:NBTX - the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand

Voir plus
NANOBIOTIX to Participate in Investor Conferences the Week of November 10th
GlobeNewswire

NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth

$71 million in funding would extend Nanobiotix cash visibility into early 2028Transaction enables Nanobiotix development beyond key milestones in head and neck cancer and lung cancerFinancing establishes financial

Voir plus
NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
GlobeNewswire

NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control

PARIS and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand

Voir plus
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.